Samsung Biologics Launches High Concentration Platform

Stock.adobe.com

Samsung Biologics launched S-HiCon, a high concentration formulation platform for the development and manufacturing of high-dose pharmaceuticals.¹ The platform is designed to improve and increase drug delivery and stability and can reportedly achieve stable liquid formulation for over 200 mg/mL subcutaneous administration. This is the latest product to be offered by the company focused on high quality drug development.

In a press release, Samsung Biologics executive vice president and Head of CDO development Brian Hosung Min said, “Our new platform will enable us to provide innovative solutions for clients requiring low to ultra-high concentration formulation to develop advanced therapeutics. Samsung Biologics is committed to providing customized services by leveraging our expertise and track record in contract development."

In late September of this year, Samsung Biologics announced two development platforms: S-AfuCHO, a cell line platform, and S-OptiCharge, an upstream process platform.² Both platforms were showcased at BioProcess International 2024.

Jahoon Kang, vice president of CDO at Samsung Biologics said in a press release, “Our new platforms are expected to provide clients with high-performing solutions for their molecules to reduce risks and support successful development. We will continue to develop innovative solutions to proactively address the evolving needs of our clients and meet increased demand for complex and high-concentration biopharmaceuticals."

In August of this year, Samsung Biologics joined the Pharmaceutical Supply Chain Initiative as a supplier partner.³ At the time, the company’s president and CEO John Rim said in a press release, “We are pleased to join the PSCI and hope to actively support collective actions to improve supply chain management. As part of our commitment to deliver safe, high-quality biomedicines, we will incorporate PSCI principles into our business practices and promote responsible conduct among our suppliers to drive sustainable change across the supply chain, contributing to a healthier future."

Prior to that, SamBiologics announced a partnership with LegoChem Biosciences, a biotech company focused on antibody-drug conjugate (ADC) programs.⁴ Under the terms of the agreement, Samsung Biologics would develop and manufacture ADC candidates based on LegoChem’s R&D.

In a press release issued at the time, Rim said, “Collaboration between Samsung Biologics and LegoChem Biosciences will enable us to deliver on our common goal to develop and manufacture efficient and safe therapeutics for patients. We look forward to working with LegoChem Biosciences to support their pipeline of innovative ADC candidates and secure new opportunities in the fast-growing ADC field."

In the same press release, LegoChem Biosciences president and CEO Yong-Zu Kim said, “LegoChem Biosciences had previously supplied antibodies for ADC through only overseas companies, but we expect that we will be able to secure a stable domestic supply chain through this contract.”

Also, in November of 2023, Samsung Biologics hosted its inaugural Supplier ESG Day, during which it shared strategies to push both ESG and actions to decarbonize.⁵ At the time, Rim said, “Since a majority of healthcare emissions are created in the manufacturing supply chains, it is critical for us to work together at every level to become greener and more circular. By connecting our suppliers with resources to help them assess their performance and opportunities to go beyond carbon emissions reductions, we are building a more transparent and responsible value chain."

He continued, “We are pleased to share our progress towards our emissions reduction targets and the responsible business practices we are implementing to mitigate climate change risks. We will continue to amplify our efforts to achieve our carbon ambition, while continuing to support our clients to deliver therapies to millions of patients worldwide."

Sources

1. Samsung Biologics Launches High-Concentration Formulation Platform to Accelerate High-Dose Drug Development. Samsung Biologics. October 14, 2024. https://www.prnewswire.com/news-releases/samsung-biologics-launches-high-concentration-formulation-platform-to-accelerate-high-dose-drug-development-302274810.html
2. Samsung Biologics Launches Development Platforms for Enhanced Therapeutic Efficacy. Samsung Biologics. September 25, 2024. Accessed October 14, 2024. https://www.prnewswire.com/news-releases/samsung-biologics-launches-development-platforms-for-enhanced-therapeutic-efficacy-302258423.html
3. Samsung Biologics Joins the Pharmaceutical Supply Chain Initiative as Supplier Partner. Samsung Biologics. August 6, 2024. Accessed October 14, 2024. https://www.prnewswire.com/news-releases/samsung-biologics-joins-the-pharmaceutical-supply-chain-initiative-as-supplier-partner-302214949.html
4. Samsung Biologics Partners with LegoChem Biosciences for ADC Development and Manufacturing. Samsung Biologics. February 7, 2024. https://www.prnewswire.com/news-releases/samsung-biologics-partners-with-legochem-biosciences-for-adc-development-and-manufacturing-302055657.html
5. Samsung Biologics Engages Suppliers to Advance Global Decarbonization Targets. Samsung Biologics. November 28, 2023. Accessed October 14, 2024. https://www.prnewswire.com/news-releases/samsung-biologics-engages-suppliers-to-advance-global-decarbonization-targets-301998662.html